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Improvement of type 2 diabetes mellitus 
control with hydroxychloroquine added to 
triple oral antidiabetis drugs: a case report
ABSTRACT 
Hydroxychloroquine, an antimalarial drug has also 
been found to possess antidiabetic action. It inactivates 
insulin degradation enzymes and also delays the dis-
sociation of insulin from the insulin receptor thus also 
lowering the insulin resistance and increasing insulin 
sensitivity. Here we report a case of a male patient 
with uncontrolled type 2 diabetes mellitus (T2DM) who 
obtained a better glycemic control when hydroxychlo-
roquine was added to the existing pharmacotherapy.
The patient has been taking metformin, glimepiride 
and acarbose for the last 2 years but his diabetes 
was poorly controlled with glycated haemoglobin 
(HbA1c) of 9.6%. Patient was proposed to intensify the 
treatment with insulin however he refused it. He was 
subsequently prescribed hydroxychloroquine 400 mg. 
Patient responded well to the therapy of hydroxy-
chloroquine and subsequent follow-ups showed good 
glycaemic control. (Clin Diabetol 2017; 6, 6: 211–214)
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Introduction 
Type 2 diabetes mellitus (T2DM) is a heterogene-
ous disease characterized by chronic hyperglycemia 
caused by increased insulin resistance and impaired 
insulin secretion. The prevalence of T2DM is rising in 
both developed and developing countries. T2DM and 
its complications constitute a major worldwide public 
health concern and are associated with considerable 
morbidity and mortality [1]. 
In T2DM, controlling blood glucose level is of 
vital importance in order to prevent microvascular 
and macrovascular complications [2]. Blood glucose 
control is generally achieved by the administration of 
oral antidiabetic drugs (OADs) or insulin along with 
physical exercise and dietary restrictions. In the man-
agement of T2DM, metformin is generally prescribed as 
first-line therapy and when it loses effectiveness, other 
OADs are added, with sulfonylureas being preferred as 
second-line treatment. It is observed that many patients 
become unresponsive to the combination of metformin 
and sulfonylureas over a period of time, which neces-
sitates the addition of a third-line agent. 
We report the case of a patient with T2DM uncon-
trolled with the use of metformin, sulfonylurea and 
acarbose combination who’s blood glucose control 
was improved when hydroxychloroquine was added 
to the therapy.
Case presentation
Patient characteristics and diagnosis 
A 51-year-old man presented at our clinic with 
uncontrolled T2DM. A medical examination conducted 
way back in 2008 had revealed impaired glucose toler-
ance. Lifestyle modification was recommended at that 
time but the patient failed to follow it.
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4 years later, in February 2012, he was diagnosed 
with T2DM and was prescribed OADs to control blood 
glucose levels. During the early stages, he had received 
monotherapy with metformin hydrochloride but it was 
no longer effective after 3 years of treatment, even after 
an increase in the dosage. Therefore, additional OADs 
were introduced. After addition, the patient was on 
the following OHA therapy-metformin hydrochloride, 
1000 mg/day; glimepiride, 4 mg/day; acarbose, 300 
mg/day. Insulin therapy was recommended at that time 
to achieve glycemic control and to prevent diabetic 
complications but the patient refused it. 
The patient presented at our clinic on February 
10, 2017, seeking to reduce blood glucose levels with 
OADs. On presentation, his fasting blood glucose was 
345 mg/dL and had glycated haemoglobin (HbA1c) 
9.6%. However, he did not complain of symptoms of 
diabetes decompensation and was following exercise 
and dietary recommendations. 
Patient physical examination: weight: 80 kg (178 lb); 
height: 157 cm (5’2”); body mass index (BMI): 32.6 kg/m2. 
Blood pressure: lying, right arm 154/96 mm Hg; sitting, 
right arm 140/90 mm Hg. Pulse: 88 bpm; Respiratory 
rate: 20 per minute. Eyes: corrective lenses, pupils 
equally reactive to light. Ophthalmological examination 
revealed clear fundus, no arteriolovenous nicking and 
no evidence of retinopathy. Thyroid glands and lungs 
were normal in physical examination. 
The heart rate and rhythm were regular, no mur-
murs or gallops were found. Vascular assessment 
revealed no carotid bruits, femoral, popliteal, and 
dorsalis pedis pulses were bilaterally palpable normally. 
Neurological assessment showed diminished vibration 
sense in the forefoot, ankle reflexes were absent and 
monofilament (5.07 Semmes-Weinstein) was felt only 
above the ankle. 
Laboratory testing
Results of laboratory tests done on 10th Feb 2017 
were as follows: fasting blood glucose (FBG): 345 mg/dl; 
HbA1c: 9.6%; creatinine: 1.0 mg/dL, blood urea nitrogen: 
18 mg/dL, sodium: 141 mg/dL, potassium: 4.3 mg/dL, 
total cholesterol: 162 mg/dL, HDL cholesterol: 43 mg/dL, 
LDL cholesterol (calculated): 84 mg/dL, triglycerides: 
442.48 mg/dL, cholesterol-to-HDL ratio: 3.8; urine 
microalbumin: 45 mg (normal: < 30 mg).
Change in treatment regimen 
The physical examination of the patient showed 
signs of peripheral neuropathy and the laboratory ex-
amination showed poor glycemic control. This patient 
needs urgent intervention to control blood glucose 
level, preferably insulin therapy. But as the patient 
expressed anxiety over the use of injectable insulin, 
hydroxychloroquine 400 mg per day was added to the 
existing therapy. 
Treatment outcomes
The patient continued his modified drug therapy, 
exercise, and dietary control from 10th February 2017 
for a period of approximately 24 weeks. Regular tests 
were performed in the interim period to monitor 
glycemic control. Baseline FBG and HbA1c were 345 
mg/dL and 9.6% respectively. Patient’s FBG and HbA1c 
reduced by 70.72% and 32.29% respectively from 
baseline within a period of 24 weeks. Ophthalmologic 
examination was performed which revealed no signs 
of retinopathy. Thus target HbA1c levels were achieved 
with the addition of hydroxychloroquine 400 mg per 
day and the therapy was well tolerated by the patient. 
The results of the follow-up are provided in the 
Figure 1 and Figure 2. 
Discussion
Hydroxychloroquine is the hydroxyl derivative of 
chloroquine. It is used, either alone or in combination 
with other agents, in the management of systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) 
and other autoimmune diseases [3].
Hydroxychloroquine has also been found to pos-
sess antidiabetic effect. It inactivates the insulin deg-
radation enzymes and also delays the dissociation of 
insulin from the insulin receptor [4, 5]. It also lowers 
the insulin resistance, improves b-cell function and 
increases insulin sensitivity [6, 7]. In one observational 
study conducted by Wasko M et al., long term use of 
hydroxychloroquine was associated with 77% reduced 
the risk of incident diabetes [8]. Few case reports have 
been also published indicating hypoglycemic effect of 
hydroxychloroquine. 
Antidiabetic effect of hydroxychloroquine has been 
explored by many investigators. Gerstein H et al. [9] ob-
served an improvement in glycemic control in patients 
with T2DM who were unresponsive to sulfonylurea. In 
that particular study, addition of hydroxychloroquine to 
sulfonylurea decreased HbA1c by an absolute amount 
of 1.02% compared to placebo. 
A double-blinded, randomized study of 267 
patients with uncontrolled T2DM was conducted by 
Pareek et al. [10] in 2014 in India. This study conclu-
sively showed that hydroxychloroquine had a similar 
anti-hyperglycaemic effect as pioglitazone among 
the patients refractory to metformin and sulfonylurea 
treatment. Based on this study, hydroxychloroquine 
400 mg has been officially approved by drug regulatory 
authority of India to improve glycemic control of T2DM 
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patients on metformin, sulfonylurea combination as an 
adjunct to diet and exercise therapy. 
This patient has been suffering from T2DM for 
a period of 5 years. He has been on triple drug combi-
nation therapy of metformin, glimepiride and acarbose 
but still his blood glucose was not well controlled. He 
presented to the clinic on February 2017 with poor 
glycemic control and diminished vibration sensation in 
the lower extremities. This patient required an intensive 
add-on therapy. He refused insulin therapy because of 
fear of injection. In this scenario, having limited options 
we put the patient on hydroxychloroquine 400 mg 
once a day in addition to existing triple OAD combina-
tion therapy. At the end of 24 weeks of treatment the 
patient achieved good glycemic control. In patients 
who are refractory to the combination treatment of 
metformin and sulphonylurea and reluctant to inject-
able therapy, hydroxychloroquine should be considered 
to bring down blood glucose levels. 
However, there are some adverse effects reported 
for hydroxychloroquine which include gastrointestinal 
upset, infrequent central nervous system effects like 
headache, pruritus, acute generalized dermatologic 
eruptions and hyperpigmentation [11]. Hypoglycemia 
has also been reported when hydroxychloroquine is 
administered with OADs and insulin for which, re-
duction in the dosage of OADs and insulin has been 
recommended [12]. 
Retinal toxicity is an important concern linked with 
the use of hydroxychloroquine. In a study done by Ma-
vrikakis et al. [13] among 400 patients, the incidence of 
retinopathy was observed to be 0.5% when the drug 
was used for 8.7 years. The risk of retinopathy increases 
with higher dosage (> 5.0 mg/kg body weight), use 
for more than five years, pre-existing renal disease, 
maculopathy and simultaneous tamoxifen use. The 
2016 American Academy of Ophthalmology (AAO) 
guidelines [14] recommended that, baseline ophthal-
Figure 2. Change in glycated haemoglobin (HbA1c) levels
Figure 1. Change in fasting blood glucose (FBG) levels
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mological screening should be done before initiation 
of hydroxychloroquine therapy and yearly screening 
should be performed after five years of use when other 
concomitant risk factors are absent. Regular annual 
ophthalmological screening is recommended for the 
patients with risk factors.
Conclusion 
The glycemic control gained by the patient dis-
cussed in this case study substantiates the effective-
ness of hydroxychloroquine as add-on therapy in 
T2DM. Addition of hydroxychloroquine exerted good 
glycemic control in the patient who was refractory to 
combination of OADs. The outcome of this case study 
indicates that, hydroxychloroquine has a potential to 
become an important alternative in the management 
of T2DM in the future.
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